Immunochina Pharmaceuticals’ IM19 CAR-T Therapy Accepted for Review by NMPA
Beijing-based biotech company Immunochina Pharmaceuticals has announced that the National Medical Products Administration (NMPA) has...
Huadong Medicine
J&J’s Stelara Faces New Biosimilar Competition in China with CSPC Pharmaceutical’s Entry
Johnson & Johnson (J&J, NYSE: JNJ)’s auto-immune disease drug Stelara (ustekinumab) is set to encounter...
China Resources Double-Crane Gets NMPA Approval for Semaglutide Biosimilar Clinical Trial
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced that it has received clinical...
AbbVie’s Elahere Receives EC Approval for FRα-Positive Ovarian Cancer Treatment
US-based AbbVie (NYSE: ABBV) has announced the European Commission (EC) approval for its antibody drug...
Huadong Medicine’s DR10624 Receives NMPA Approval for MAFLD and MASH Clinical Trials
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Huadong Medicine’s HDM1005 Receives FDA Approval for MASH Clinical Study
Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that it has...
Huadong Medicine’s Biosimilar SaiLeXin Receives First National Prescription in China
China-based pharmaceutical company Huadong Medicine Co., Ltd (SHE: 000963) has announced a significant milestone with...
Huadong Medicine Co., Ltd Receives NMPA Approval for Stelara Biosimilar SaiLeXin
Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that it has...
Huadong Medicine Gets Green Light for HPK1 PROTAC Drug HDM2006 in Advanced Solid Tumors
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced that it has...
Huadong Medicine Secures NMPA Approval for Semaglutide Biosimilar, Aims to Capture Weight Loss Market
Nanjing-based Huadong Medicine Co., Ltd (SHE: 000963) has received clinical trial approval from China’s National...
Huadong Medicine Gets NMPA Green Light for Clinical Trials of Roflumilast Cream
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced that it has...
Huadong Medicine’s V20 Device Receives NMPA Approval for Market Launch
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced that it has...
Huadong Medicine Secures Exclusive Rights to Janagliflozin for Type 2 Diabetes Treatment in China
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has entered into a licensing...
Huadong Medicine Secures Licensing Deal with IMBiologics for Autoimmune Drug Candidates
Huadong Medicine Co., Ltd. (SHE: 000963), a Chinese pharmaceutical company, has entered into a licensing...
Huadong Medicine Expands Global Footprint with Launch of Aesthetic Injection MaiLi in Singapore
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced the international expansion...
Huadong Medicine Secures Exclusive Rights to Immunochina’s CAR-T Therapy in China
China-based pharmaceutical company Huadong Medicine Co., Ltd (SHE: 000963) has entered into a licensing agreement...
Jiangsu QYuns Therapeutics and Huadong Medicine Partner on QX005N Injection Development and Promotion
Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has entered...
Huadong Medicine to Expand TCM Footprint with Acquisition of Hengba Pharmaceutical
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced its intention to...
Huadong Medicine’s Partner Arcutis Gets FDA Nod for Roflumilast Cream
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, announced that its co-development partner...
Huadong Medicine Secures Exclusive Rights to Oral Edaravone Candidate TTYP01 in Major Licensing Deal
Huadong Medicine Co., Ltd (SHE: 000963), a prominent pharmaceutical company in China, has entered into...